News

The American Journal of Managed Care2d
Diagnostic Dilemmas: Barriers to Timely Detection of IPF and PPF
Panelists discuss how progressive pulmonary fibrosis (PPF) and idiopathic pulmonary fibrosis (IPF), though distinct in ...
The American Journal of Managed Care2d
Leveraging the Multidisciplinary Team to Overcoming Diagnosing IPF or PPF
Panelists discuss how progressive pulmonary fibrosis (PPF) and idiopathic pulmonary fibrosis (IPF), though distinct in ...
Pulmonary Fibrosis News7d
Nerandomilast slows lung function decline in IPF, PPF: Clinical trials
Nerandomilast slowed lung function decline in people with IPF and PPF after a year of treatment, according to data from two ...
Applied Clinical Trials Online15d
Nerandomilast Meets Primary Endpoints in Phase III IPF and PPF Trials, Shows Significant Lung Function Preservation
Data from the FIBRONEER-IPF and FIBRONEER-ILD studies, published in The New England Journal of Medicine, highlight ...
PMLive10d
Boehringer’s nerandomilast shows lung function benefit in phase 3 IPF and PPF trials
Results presented at this year’s American Thoracic Society International Conference showed that the trials met their primary ...
abc2718d
Global phase III trials demonstrate that nerandomilast slowed lung function decline in IPF and PPF, with similar discontinuation rates to placebo
"After several challenges in the scientific community to bring forward new clinical data, IPF and PPF continue to take a devastating toll on patients,” said Toby Maher, M.D., Ph.D., Professor of ...
Healio17d
Nerandomilast lowers FVC decline in progressive pulmonary fibrosis at 52 weeks
Two doses of 52-week nerandomilast, a phosphodiesterase 4B inhibitor, lowered FVC decline vs. placebo in patients with progressive pulmonary fibrosis, according to results published in The New England ...
Mena FN18d
Global Phase III Trials Demonstrate That Nerandomilast Slowed Lung Function Decline In IPF And PPF, With Similar Discontinuation Rates To Placebo
1,2 FVC is a measure of lung function. 3 "After several challenges in the scientific community to bring forward new clinical data, IPF and PPF continue to take a devastating toll on patients ...
Pharmabiz16d
Boehringer Ingelheim announces global phase III trials demonstrate that nerandomilast slowed lung function decline in IPF & PPF, with similar discontinuation rates to placebo
These studies evaluated nerandomilast, an investigational oral, preferential inhibitor of phosphodiesterase 4B (PDE4B), in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary ...